Publication Name	World Journal of Hepatology
Manuscript ID	17292
Country	Japan

Received	2015-02-28 10:19
Peer-Review Started	2015-03-01 14:35
First Decision by Editorial Office Director
Return for Revision	2015-04-20 16:51
Revised	2015-05-03 10:45
Publication Fee Transferred
Second Decision by Editor	2015-08-21 13:09
Second Decision by Editor-in-Chief
Final Decision by Editorial Office Director	2015-09-07 08:33
Articles in Press	2015-09-07 08:33
Edit the Manuscript by Language Editor	2015-10-26 22:15
Typeset the Manuscript	2015-11-10 17:22
Publish the Manuscript Online	2015-11-18 11:12

ISSN	1948-5182 (online)
Open Access	This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright	© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Gastroenterology & Hepatology
Manuscript Type	Prospective Study
Article Title	Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C
Manuscript Source	Unsolicited Manuscript
All Author List	Satoshi Hiramine, Norihiro Furusyo, Eiichi Ogawa, Makoto Nakamuta, Eiji Kajiwara, Hideyuki Nomura, Kazufumi Dohmen, Kazuhiro Takahashi, Takeaki Satoh, Koichi Azuma, Akira Kawano, Toshimasa Koyanagi, Kazuhiro Kotoh, Shinji Shimoda and Jun Hayashi
Funding Agency and Grant Number
Corresponding Author	Jun Hayashi, MD, PhD, Kyushu General Internal Medicine Center, Hara-Doi Hospital, 6-40-8 Aoba, Higashi-ku, Fukuoka 813-8588, Japan. hayashij@gim.med.kyushu-u.ac.jp
Key Words	Chronic hepatitis C; Direct-acting antiviral agent; Rapid virological response; Early virological response; Response-guided treatment
Core Tip	Although an undetectable viral level at week 4 or 12 is a good predictor of the outcome of hepatitis C for conventional interferon therapy without direct-acting antiviral agents (DAAs); the transition of the viral level during DAA therapy has not been well documented. In this prospective multicenter study, we frequently tested 253 patients to investigate viral activity during triple therapy containing telaprevir, the first approved DAA, and found that an undetectable viral level at week 6 was the most effective predictor of disease outcome. Our findings suggest that the most predictive time point in DAA therapy is different from conventional therapy markers.
Publish Date	2015-11-18 11:12
Citation	Hiramine S, Furusyo N, Ogawa E, Nakamuta M, Kajiwara E, Nomura H, Dohmen K, Takahashi K, Satoh T, Azuma K, Kawano A, Koyanagi T, Kotoh K, Shimoda S, Hayashi J. Importance of virological response in the early stage of telaprevir-based triple therapy for hepatitis C. World J Hepatol 2015; 7(26): 2688-2695
URL	http://www.wjgnet.com/1948-5182/full/v7/i26/2688.htm
DOI	http://dx.doi.org/10.4254/wjh.v7.i26.2688

Full Article (PDF)	WJH-7-2688.pdf
Full Article (Word)	WJH-7-2688.doc
Manuscript File	17292-Review.docx
Answering Reviewers	17292-Answering reviewers.pdf
Audio Core Tip	17292-Audio core tip.wav
Copyright License Agreement	17292-Copyright assignment.pdf
Signed Informed Consent Form(s) or Document(s)	Informed_Consent_Statement_20150227204423.doc
Peer-review Report	17292-Peer-review(s).pdf
Scientific Misconduct Check	17292-Scientific misconduct check.pdf